Maxim Group Initiates Coverage On Mira Pharmaceuticals with Buy Rating, Announces Price Target of $3.5

Maxim Group analyst Jason McCarthy has initiated coverage on Mira Pharmaceuticals (NASDAQ: MIRA) with a Buy rating. The firm has set a price target of $3.50 for the stock.